{"id":23642,"date":"2024-06-25T08:22:55","date_gmt":"2024-06-25T12:22:55","guid":{"rendered":"https:\/\/www.drugpatentwatch.com\/blog\/?p=23642"},"modified":"2026-04-19T21:24:59","modified_gmt":"2026-04-20T01:24:59","slug":"uspto-study-reveals-trends-and-insights-into-drug-patent-and-exclusivity-trends-in-the-pharmaceutical-industry","status":"publish","type":"post","link":"https:\/\/www.drugpatentwatch.com\/blog\/uspto-study-reveals-trends-and-insights-into-drug-patent-and-exclusivity-trends-in-the-pharmaceutical-industry\/","title":{"rendered":"Drug Patent Exclusivity: What the USPTO Study Actually Tells IP Teams, Portfolio Managers, and Generic Challengers"},"content":{"rendered":"\n

Executive Summary and Key Findings <\/h2>\n\n\n\n
\"\"<\/figure>\n\n\n\n

The USPTO’s Drug Patent and Exclusivity Study, produced in collaboration with the FDA at the request of Senator Thom Tillis (R-NC), is the most rigorous government-led empirical challenge to date of the methodology used by patent critics such as the Initiative for Medicines, Access & Knowledge (I-MAK). Its core finding: raw patent counts do not predict the duration of market exclusivity. For the 13 drugs in the study’s 25-NDA sample that had faced generic competition by September 2023, actual exclusivity from NDA approval to first generic launch averaged 11.4 years, ranging from approximately 3 to 16.4 years. Not one product in the sample held exclusivity for the full statutory 20-year patent term.<\/p>\n\n\n\n

That number, 11.4 years, is the study’s single most operationally important output. It anchors every downstream argument about systemic patent abuse, pricing, and competitive harm. But analysts who stop there miss the more nuanced conflict the study has accelerated. The Federal Trade Commission, operating under a distinct statutory mandate, simultaneously launched an enforcement campaign targeting what it frames as ‘improper’ Orange Book patent listings, sending warning letters covering more than 400 patents across blockbuster franchises from AstraZeneca, GlaxoSmithKline, Novo Nordisk, and others. The two agencies are not reaching different conclusions about the same evidence. They are asking fundamentally different legal questions.<\/p>\n\n\n\n

This pillar page synthesizes the study’s methodology and findings, the patent thicket debate’s empirical evidence base, the mechanics of Hatch-Waxman litigation, FDA regulatory exclusivity architecture, PTAB statistics specific to biopharma, and the FTC’s Orange Book enforcement posture. It also provides IP valuation frameworks for specific drug assets, a structured technology roadmap of evergreening tactics, and an investment strategy section calibrated to the current regulatory environment.<\/p>\n\n\n\n

\n\n\n\n

Section I: The USPTO Study: Mandate, Methodology, and What It Actually Measures <\/h2>\n\n\n\n

Genesis: The Tillis Request and the I-MAK Problem<\/strong><\/h3>\n\n\n\n

The study’s origin matters for interpreting its conclusions. Senator Tillis wrote to the USPTO in January and April 2022 requesting an independent, fact-based analysis to assess claims being made by what he characterized as ‘anti-patent activists.’ The primary target of his concern was I-MAK, whose widely cited reports contend that pharmaceutical companies systematically abuse the patent system to create ‘patent thickets’ and extend drug monopolies for decades.<\/p>\n\n\n\n

I-MAK’s methodology counts all patents and patent applications associated with a drug, including those not listed in the Orange Book, those pending examination, and those ultimately abandoned. Their numbers are large. A 2020 I-MAK analysis of Humira counted 136 granted patents and over 247 applications. The USPTO’s explicit response was to reject this counting approach as ‘an imprecise way to measure the intellectual property landscape of a drug product,’ on the grounds that only granted, Orange Book-listed patents can trigger the Hatch-Waxman 30-month stay and therefore only those patents directly affect the timing of generic entry.<\/p>\n\n\n\n

This methodological dispute is not trivial. It explains why the same drug can appear to have 136 patents blocking competition in one analysis and a far smaller, more bounded portfolio in the USPTO’s framework. Neither count is ‘wrong’ in a factual sense. They measure different things. The policy question is which measure most accurately captures competitive harm.<\/p>\n\n\n\n

Sample Design: 25 NDAs, 13 Active Ingredients, Deliberate Selection<\/strong><\/h3>\n\n\n\n

The study’s sample was not random. The USPTO and FDA selected 25 NDAs representing 13 active ingredients, choosing products that were simultaneously top revenue generators in 2017 (apixaban, lenalidomide, pregabalin), among the most prescribed branded products (atorvastatin, amlodipine besylate, albuterol sulfate), and specifically cited in the analyses that prompted the Tillis request. The analytic timeframe ran from 2005 to 2018, aligning with the UC Law San Francisco Evergreen Drug Patent Database’s coverage window.<\/p>\n\n\n\n

For each NDA, the agencies compiled patent expiration dates independently, accounting for patent term adjustments (PTA), patent term extensions (PTE), and any terminal disclaimers. Rather than relying on dates submitted by the NDA holder to the FDA, the USPTO performed its own calculations. This approach is more rigorous than most external analyses, which typically rely on publicly reported expiration dates that may not reflect PTE calculations or terminal disclaimer effects.<\/p>\n\n\n\n

The study deliberately excluded two categories of patents that critics routinely include: patents not listed in the Orange Book, and pending or abandoned applications. The exclusion of pending applications is particularly significant given that one deterrent function of a patent portfolio is the uncertainty it creates before applications are resolved. The USPTO’s position is that unenforceable rights cannot constitute a legal barrier to competition. Critics’ position is that the act of filing, even if later abandoned, imposes real costs on generic firms assessing the litigation risk of an ANDA filing.<\/p>\n\n\n\n

What the Study Was Not Designed to Measure<\/strong><\/h3>\n\n\n\n

Understanding the study’s scope limitations is as important as understanding its findings. The report did not examine drug pricing, the impact of generic entry on market share dynamics, manufacturing or regulatory barriers to generic entry, the in terrorem deterrent effect of large patent portfolios on potential generic challengers, or the transaction costs imposed on generic firms navigating a dense Orange Book. The study’s stated purpose was to provide ‘a baseline approach that researchers and policymakers can use in future analysis,’ not to deliver a comprehensive verdict on the competitive health of the pharmaceutical market.<\/p>\n\n\n\n

Key Takeaways: Section I<\/strong><\/h3>\n\n\n\n

The USPTO study’s core methodological contribution is the construction of a direct causal chain from NDA approval to first generic launch, measured against the Orange Book patent universe only. Its findings are internally valid within that scope. The 11.4-year average exclusivity figure is real and meaningful. What it does not capture is whether the process of reaching that endpoint, the patent challenges filed, the 30-month stays triggered, the settlement agreements negotiated, and the potential challengers deterred from ever filing, represents an efficient or distorted competitive market. That question remains open.<\/p>\n\n\n\n

\n\n\n\n

Section II: The 11.4-Year Reality: Deconstructing Average Market Exclusivity <\/h2>\n\n\n\n

The Range Matters as Much as the Mean<\/strong><\/h3>\n\n\n\n

The 11.4-year average exclusivity period across 13 products with generic entry obscures a distribution that runs from roughly 3 years to 16.4 years. That range matters operationally. A 3-year exclusivity window changes the economics of drug development and commercialization entirely relative to a 16-year window. Products at the low end of the range faced rapid generic challenge, often through successful Paragraph IV litigation. Products at the high end tend to be those with complex formulations, strong composition-of-matter patents, or both.<\/p>\n\n\n\n

The USPTO’s finding aligns with external academic literature. Studies by Grabowski and colleagues, as well as analyses published through the National Bureau of Economic Research, have reported average exclusivity periods for new molecular entities in the range of 11.3 to 13 years. The consistency across methodologies lends credibility to the figure, though the NBER work also identifies significant heterogeneity across therapeutic areas and drug classes.<\/p>\n\n\n\n

Patent Expiration Is Not the Same as Generic Entry<\/strong><\/h3>\n\n\n\n

One of the study’s more operationally useful observations is that patent expiration dates do not reliably predict generic launch dates. Generic entry can occur before all listed patents expire through successful Paragraph IV litigation, court-approved settlement agreements specifying an entry date, or the grant of a license as part of litigation resolution. Entry can also lag patent expiration when manufacturing complexity, bioequivalence challenges, REMS restrictions, or limited commercial incentive delay ANDA filings or approvals.<\/p>\n\n\n\n

The study’s case studies illustrate both directions. LIPITOR (atorvastatin) and REVLIMID (lenalidomide) saw generic entry following settlement agreements, with generic launch occurring while some follow-on patents remained technically in force. VENTOLIN HFA (albuterol sulfate) and AMBIEN (zolpidem) had no generic competitors even after Orange Book-listed patent expiration, suggesting that non-IP barriers controlled the competitive timeline more than the patent estate.<\/p>\n\n\n\n

For IP teams and portfolio managers, this finding argues against treating patent expiration calendars as mechanical predictors of loss of exclusivity (LOE). Patent-expiration-based LOE modeling requires adjustment for litigation probability, settlement likelihood, manufacturing complexity, and REMS status. Straight patent-expiration modeling systematically misstates LOE timing in both directions.<\/p>\n\n\n\n

The 12 Products Without Generic Entry: What They Tell You<\/strong><\/h3>\n\n\n\n

Twelve of the 25 NDAs in the study had not faced generic competition by September 2023. The USPTO’s analysis of these products is less detailed than the 13 with generic entry, largely because the primary outcome variable (first generic launch) had not yet occurred. This creates an analytical asymmetry: the study’s conclusions about average exclusivity derive entirely from products whose competitive story has already played out, which may not represent the distribution of outcomes for currently active, heavily patented blockbusters.<\/p>\n\n\n\n

This is not a criticism of the methodology. It is a structural feature of any study measuring a real-world event that has not yet occurred for all subjects. It does mean that the 11.4-year average should be interpreted as a retrospective finding applicable to the specific drug cohort analyzed, not as a forward-looking prediction for drugs currently protected by dense Orange Book portfolios.<\/p>\n\n\n\n

Key Takeaways: Section II<\/strong><\/h3>\n\n\n\n

The 11.4-year figure is empirically grounded but applies to a specific, deliberately selected cohort. The range of 3 to 16.4 years reflects structural variation that aggregation obscures. Patent expiration is not a reliable LOE signal. IP teams, commercial leads, and portfolio managers need product-specific analysis that integrates patent strength, litigation history, ANDA filing activity, and non-IP barriers before making launch timing assumptions.<\/p>\n\n\n\n

\n\n\n\n

Section III: Evergreening and Patent Thickets: A Structured Evidence Review <\/h2>\n\n\n\n

Defining the Terms Precisely<\/strong><\/h3>\n\n\n\n

‘Evergreening’ and ‘patent thicket’ are terms that appear in both peer-reviewed literature and advocacy materials, often without precise definition. For analysis purposes, the terms should be defined operationally.<\/p>\n\n\n\n

Evergreening, in its technical sense, refers to obtaining secondary patents on modifications to an existing drug, such as new salts, polymorphs, prodrugs, formulations, delivery devices, or dosing regimens, where those modifications provide no clinically meaningful improvement over the existing product. The intent, from a critical perspective, is to extend effective market protection beyond the expiration of the primary composition-of-matter patent.<\/p>\n\n\n\n

A patent thicket is a dense, overlapping cluster of multiple patents on a single product or technology area such that any competitor seeking to market a generic or biosimilar version must either license from or litigate against the innovator across every patent in the cluster. The strategic value of a thicket is not necessarily the strength of any individual patent but the cumulative cost and complexity of challenging all of them.<\/p>\n\n\n\n

The distinction between legitimate lifecycle management and anticompetitive thicket construction is genuinely contested, both legally and empirically. That contest is where the most significant IP and investment risk currently resides.<\/p>\n\n\n\n

The Feldman Data: 78% of Newly Patented Drugs Were Existing Medicines<\/strong><\/h3>\n\n\n\n

Professor Robin Feldman’s analysis, covering 2005 to 2015, found that 78% of drugs associated with new patents were existing medicines rather than new molecular entities. This figure is the most commonly cited empirical support for the prevalence of evergreening. It is important to read it carefully. The study identifies the existence of secondary patenting on existing drugs at scale. It does not, by itself, establish that those secondary patents lacked inventive merit, that they delayed generic entry, or that they generated any specific amount of competitive harm.<\/p>\n\n\n\n

The USPTO’s methodological response to Feldman-style analyses is to focus on whether those secondary patents actually affected the timing of generic entry. The study’s finding of no clear correlation between patent count and exclusivity duration is the closest the report comes to directly addressing the Feldman data. If secondary patents on existing drugs were systematically extending exclusivity, one would expect to see a positive correlation between patent count and exclusivity length. The study found none for its sample.<\/p>\n\n\n\n

Critics would respond that the absence of measured exclusivity extension does not rule out a deterrent effect. A generic firm that decides not to file an ANDA because the litigation cost of challenging 30 patents is prohibitive does not appear in any exclusivity duration dataset. It is an absence of competitive entry that leaves no data trace in the outcome variable the USPTO measured.<\/p>\n\n\n\n

The Humira Case: IP Valuation of AbbVie’s Adalimumab Portfolio<\/strong><\/h3>\n\n\n\n

AbbVie’s adalimumab (HUMIRA) is the paradigmatic case for patent thicket analysis, and its IP valuation warrants detailed examination.<\/p>\n\n\n\n

Adalimumab’s primary composition-of-matter patents expired in the U.S. in 2016. At that point, AbbVie’s market protection derived from a portfolio that I-MAK counted at 136 granted patents, with 89% filed after initial FDA approval. AbbVie constructed this portfolio across multiple dimensions: formulation patents covering single-concentration (50 mg\/mL) and double-concentration (100 mg\/mL) presentations, method-of-use patents for each of adalimumab’s 10+ approved indications, manufacturing process patents, device patents covering the autoinjector pen, and purity-level patents specifying allowable ranges of product-related impurities. Extensive use of terminal disclaimers tied many of these patents together into expiry clusters.<\/p>\n\n\n\n

The IP valuation consequence of this portfolio was direct and measurable. Biosimilar adalimumab products were approved and available in Europe from October 2018. U.S. biosimilar entry did not occur until January 2023, more than four years later. During that gap, AbbVie generated approximately $80 billion in cumulative U.S. net revenues from Humira. The delay was not attributable entirely to patent litigation: AbbVie entered into settlement agreements with multiple biosimilar manufacturers that granted U.S. entry rights starting in January 2023 in exchange for dropping patent challenges. The settlements themselves are evidence that the thicket functioned as designed, deterring litigation and enabling AbbVie to set the entry date commercially rather than having it determined by a court.<\/p>\n\n\n\n

From an IP valuation perspective, the Humira portfolio generated roughly $20-25 billion in additional revenue that would not have been available if U.S. biosimilar entry had matched the European timeline. That revenue, discounted and risk-adjusted, was the economic value of the thicket above and beyond what the primary composition-of-matter patents alone would have secured.<\/p>\n\n\n\n

For analysts modeling innovator revenue, this case establishes that a well-constructed secondary patent portfolio targeting a biologic with no small-molecule generic pathway can generate IP asset value running into the tens of billions of dollars. The FTC’s subsequent enforcement actions represent the first serious regulatory attempt to disrupt this model.<\/p>\n\n\n\n

Amgen’s Enbrel: A 30-Year Projected Monopoly and Its IP Architecture<\/strong><\/h3>\n\n\n\n

Etanercept (ENBREL, Amgen\/Pfizer) is a second archetype. The primary composition-of-matter patent expired in 2012. Amgen’s portfolio of 68+ patents, built around manufacturing processes, formulations, methods of use, and administration devices, has maintained U.S. market exclusivity with no biosimilar entrant as of April 2026, with projections of continued protection through approximately 2029. European biosimilar entry occurred in 2016.<\/p>\n\n\n\n

The structure of Amgen’s IP protection for Enbrel differs from Humira’s in one important respect: it relies more heavily on manufacturing process patents covering the specific cell culture and purification processes used to produce etanercept. Manufacturing process patents are generally harder for biosimilar manufacturers to design around because the molecular complexity of biologic manufacturing creates limited alternative pathways to the same product. This gives Enbrel’s protection a technical robustness that does not depend solely on litigation deterrence.<\/p>\n\n\n\n

The IP valuation implication for Enbrel is that etanercept’s residual patent estate represents a meaningful asset on Amgen’s balance sheet extending several more years, with annual revenues in the $2 billion range in the U.S. alone. For portfolio managers holding Amgen equity, the key risk variable is whether any biosimilar manufacturer successfully challenges the manufacturing process patents in federal district court or via IPR, and whether the FTC identifies any Orange Book listings covering device patents as ‘improper.’<\/p>\n\n\n\n

The Celgene\/BMS Revlimid Strategy: REMS as an IP Moat<\/strong><\/h3>\n\n\n\n

Lenalidomide (REVLIMID) illustrates a distinct evergreening mechanism that extends beyond traditional patent strategy into the regulatory exclusivity architecture. Celgene, acquired by Bristol-Myers Squibb in 2019, used its Risk Evaluation and Mitigation Strategy (REMS) for lenalidomide, a mandatory risk management program required by the FDA due to the drug’s severe teratogenicity, as a component of its competitive protection strategy.<\/p>\n\n\n\n

Generic manufacturers seeking to develop bioequivalent lenalidomide required access to the drug for bioequivalence testing. Celgene initially refused to sell reference product to generic manufacturers, citing REMS-related safety concerns. Several generic firms filed antitrust complaints alleging that Celgene was using the REMS as a pretextual barrier to generic development. The FTC investigated and ultimately reached a settlement with Celgene that required it to sell reference product to generic applicants.<\/p>\n\n\n\n

The lenalidomide REMS dispute demonstrates that evergreening-adjacent strategies extend beyond patent prosecution. For IP teams and regulatory affairs departments, this case is a reminder that the full competitive protection toolkit includes REMS restrictions, citizen petitions challenging generic approval standards, and FDA data exclusivity claims, all of which interact with the patent estate to determine the actual LOE timeline.<\/p>\n\n\n\n

Limited-volume generic entry for lenalidomide began in March 2022 following a court-approved settlement agreement that allowed Natco Pharma to market a capped quantity of generic product before full open generic competition. BMS had 70+ patents listed in the Orange Book for Revlimid, including polymorphs, methods of use, and the REMS-related patents. The negotiated entry structure preserved a premium pricing window during the transition that softened the revenue cliff materially.<\/p>\n\n\n\n

Key Takeaways: Section III<\/strong><\/h3>\n\n\n\n

Evergreening and patent thicket construction are real practices with measurable financial consequences, as the Humira, Enbrel, and Revlimid cases demonstrate concretely. The debate between the USPTO’s finding of no systemic exclusivity extension and critics’ evidence of pervasive secondary patenting is methodologically genuine, not resolvable by simply declaring one side correct. The operational question for IP teams and analysts is not whether thickets exist, but whether any specific product’s portfolio will withstand IPR challenge, FTC scrutiny, and the shifting legal interpretation of Orange Book listing eligibility. Each of those risk factors carries a specific probability distribution that belongs in any LOE model.<\/p>\n\n\n\n

\n\n\n\n

Section IV: IP Valuation Implications for Key Drug Assets <\/h2>\n\n\n\n

Framework: How Patent Portfolio Structure Translates to Asset Value<\/strong><\/h3>\n\n\n\n

A drug’s IP estate is not valued uniformly. The economic value of a patent portfolio is a function of four variables: the time remaining on each patent, the probability that each patent survives challenge (either in federal district court via Paragraph IV litigation or at the PTAB via IPR), the revenue at risk during the period of protection each patent provides, and the cost of enforcing those rights against challengers.<\/p>\n\n\n\n

For primary composition-of-matter patents on small molecules, the industry standard is to model them as high-probability assets in the early years post-approval, degrading toward a 40-60% survival probability as they approach the window of generic ANDA filing activity (typically 4-6 years before projected expiration). Secondary patents, formulation patents, and method-of-use patents are generally modeled at lower survival probabilities, often 25-50%, reflecting their higher rate of successful IPR challenges and Paragraph IV non-infringement findings.<\/p>\n\n\n\n

For biologics, the relevant framework shifts. No ANDA pathway exists for biologics. The BPCIA creates a different interplay between patents and exclusivity (detailed in Section X), and the 12-year reference product exclusivity period creates a floor on biosimilar entry timing that does not exist in the small molecule world. Biologic patent portfolios are therefore valued differently: the composition-of-matter and manufacturing process patents are primary assets, but the 12-year statutory exclusivity often binds before those patents expire, making the patent portfolio’s value contingent on extending protection past the exclusivity cliff rather than parallel to it.<\/p>\n\n\n\n

Apixaban (Eliquis): IP Valuation at the End of the Protection Window<\/strong><\/h3>\n\n\n\n

Apixaban (ELIQUIS, Bristol-Myers Squibb\/Pfizer) was one of the study’s named drugs and one of the highest-revenue products in the sample. Its primary composition-of-matter patent, U.S. 6,967,208, expired in 2023, triggering the first wave of generic ANDA filings. The Orange Book listed additional patents covering apixaban formulations, extending theoretical protection. However, multiple generic manufacturers filed Paragraph IV certifications challenging the formulation patents, and several settlement agreements allowed generic entry beginning in 2026.<\/p>\n\n\n\n

The IP valuation picture for apixaban as of April 2026 is one of managed LOE. BMS and Pfizer negotiated agreements with major generic manufacturers rather than litigating every Paragraph IV challenge to conclusion. The settlement structure allowed the innovator to model revenue decline on a known timeline rather than absorbing the risk of a court judgment that might have allowed immediate generic entry. This tradeoff illustrates the risk management function of patent litigation settlements from the innovator’s perspective: certainty about the LOE date, at the cost of earlier competitive entry than a fully successful litigation outcome would have permitted.<\/p>\n\n\n\n

For analysts, the apixaban transition demonstrates that settlement agreements are a legitimate tool for IP valuation purposes: they convert a binary litigation outcome into a negotiated entry date, which allows discounted cash flow models to treat the LOE date as known rather than probabilistic.<\/p>\n\n\n\n

Pembrolizumab (Keytruda): IP Moat Valuation for a $25 Billion Franchise<\/strong><\/h3>\n\n\n\n

Merck’s pembrolizumab (KEYTRUDA) is the world’s top-selling drug by revenue, generating approximately $25 billion annually. Its primary PD-1 antibody patents expire around 2028 in the U.S., but Merck has filed 129+ additional patents covering subcutaneous formulations, combination therapy methods, and new oncology indications. The subcutaneous pembrolizumab program is particularly significant for IP valuation purposes: Merck’s sBLA for a subcutaneous formulation was under FDA review as of late 2024, and a patent covering that delivery method, if listed in the Orange Book, would represent a new IP asset with a potentially later expiration than the original IV formulation patents.<\/p>\n\n\n\n

The IP asset value of Keytruda’s secondary patent portfolio is substantial. Each new indication approved by the FDA potentially anchors a new method-of-use patent. Given that pembrolizumab has over 45 approved indications and combination regimens, the method-of-use patent estate covers an enormous fraction of its actual clinical use. A biosimilar manufacturer would face the challenge that even if it could freely market the antibody itself after 2028, prescribers might prefer to use it in FDA-approved combination regimens covered by method-of-use patents that Merck could enforce against both the biosimilar manufacturer and potentially against providers administering the combination.<\/p>\n\n\n\n

From a portfolio manager’s perspective, the Keytruda IP moat analysis is one of the most complex in the industry. The BPCIA 12-year exclusivity (expiring around 2026 for the original approval) is already expired or expiring. The primary antibody patents expire around 2028. The 129+ secondary patents could extend meaningful IP protection further, but each patent in that portfolio carries IPR and Paragraph IV challenge risk. The fair value of Merck’s IP position requires modeling the probability-weighted survival of each patent layer independently, not treating the entire portfolio as a single asset.<\/p>\n\n\n\n

Key Takeaways: Section IV<\/strong><\/h3>\n\n\n\n

IP valuation for pharmaceutical assets requires distinguishing between patent layers by both strength and economic relevance. Composition-of-matter patents on active ingredients are the highest-value, highest-probability assets. Formulation and method-of-use patents carry lower survival probabilities. Biologic portfolios require an additional BPCIA-specific modeling layer. For specific assets like Keytruda, the complexity of the method-of-use patent estate in a multi-indication biologic creates valuation challenges that standard LOE modeling tools do not adequately capture.<\/p>\n\n\n\n

\n\n\n\n

Section V: The Orange Book as Strategic Infrastructure: Paragraph IV, 30-Month Stays, and Orange Book Listing Decisions <\/h2>\n\n\n\n

The Mechanics of the 30-Month Stay<\/strong><\/h3>\n\n\n\n

The Hatch-Waxman Act’s Paragraph IV certification mechanism is the single most operationally consequential feature of U.S. pharmaceutical patent law. When a generic manufacturer files an ANDA with a Paragraph IV certification asserting that a listed Orange Book patent is invalid, unenforceable, or not infringed, it commits a technical act of patent infringement, which gives the innovator standing to sue immediately. If the innovator files suit within 45 days of receiving notice of the Paragraph IV certification, an automatic 30-month stay takes effect, during which the FDA cannot grant final ANDA approval.<\/p>\n\n\n\n

The stay is automatic and does not require the innovator to demonstrate any likelihood of success on the merits. A patent that is commercially weak or legally vulnerable generates the same 30-month stay as an unassailable composition-of-matter patent. This feature creates a powerful incentive to list patents in the Orange Book broadly: the cost of listing is the administrative burden of the submission, while the reward is a potential 30-month delay of generic competition for each patent listed.<\/p>\n\n\n\n

The FTC’s 2023 enforcement campaign targeted precisely this incentive structure. The agency’s position is that listing patents covering drug delivery devices, such as asthma inhaler components or diabetes autoinjector mechanisms, does not comply with the statutory requirement that Orange Book patents ‘claim the drug’ or a ‘method of using the drug.’ By listing device patents and triggering 30-month stays, innovators can delay generic entry for a period that bears no relationship to the actual novelty or breadth of protection the device patent provides.<\/p>\n\n\n\n

Strategic Listing Decisions: Risk-Benefit Analysis Post-FTC Action<\/strong><\/h3>\n\n\n\n

For innovator IP teams, the FTC’s 2023 and 2024 enforcement actions have changed the calculus of Orange Book listing decisions. Before September 2023, the dominant practice was to list any patent that plausibly fell within the ‘claiming the drug or method of using the drug’ standard. After September 2023, each listing decision carries the additional risk of an FTC warning letter, a delisting demand, and potential exposure in private antitrust litigation from generic manufacturers.<\/p>\n\n\n\n

The drugs most directly affected by FTC scrutiny are GLP-1 agonists for type 2 diabetes and obesity management, including semaglutide (OZEMPIC, WEGOVY, Novo Nordisk), liraglutide (VICTOZA, Novo Nordisk), and tirzepatide (MOUNJARO, ZEPBOUND, Eli Lilly), as well as inhaled corticosteroids and bronchodilators for asthma and COPD. These products share a structural characteristic: the drug is administered via a device (autoinjector pen or inhaler) that is a significant component of the product’s commercial differentiation. Device patents on these delivery systems are commercially valuable and represent genuine innovation, but their Orange Book listing eligibility is now the subject of active FTC scrutiny.<\/p>\n\n\n\n

For Novo Nordisk’s semaglutide franchise, the FTC challenged specific Orange Book listings for OZEMPIC and VICTOZA. Novo Nordisk’s response, and the outcomes of those challenges in federal district court, will set precedent that determines the listing eligibility of device patents across the GLP-1 class. For the $40+ billion semaglutide franchise, the IP valuation consequence of that precedent is measured in billions of dollars per year of delay or acceleration of biosimilar entry.<\/p>\n\n\n\n

The First-Filer Advantage: 180-Day Generic Exclusivity as an IP Asset<\/strong><\/h3>\n\n\n\n

From the generic manufacturer’s perspective, the 180-day marketing exclusivity granted to the first ANDA applicant to file a substantially complete application with a Paragraph IV certification is itself an IP asset with significant commercial value. The first filer has the right to market its product for 180 days before any other ANDA-approved generic can enter, during which duopoly pricing between the brand and the first-filer generic typically supports margins far above those available after full generic competition develops.<\/p>\n\n\n\n

The economic value of the 180-day exclusivity depends on the revenue of the brand drug, the number of competing ANDA filers likely to enter after the 180-day window, and the pricing dynamic in the specific therapeutic class. For a $5 billion annual revenue brand with a significant price premium at generic launch, the 180-day exclusivity window can be worth $300-500 million in incremental revenue to the first-filer generic manufacturer. This is why Paragraph IV litigation strategies among generic manufacturers are often as competitive among themselves as they are against the innovator.<\/p>\n\n\n\n

Key Takeaways: Section V<\/strong><\/h3>\n\n\n\n

The Orange Book is not a passive regulatory registry. It is the operational fulcrum of Hatch-Waxman litigation strategy. For innovators, the FTC’s enforcement posture has introduced antitrust risk into listing decisions that were previously governed only by patent law. For generic manufacturers, the Paragraph IV filing strategy remains the primary tool for market entry, with 180-day first-filer exclusivity as a major commercial prize. For both sides, understanding the specific statutory criteria for Orange Book listing eligibility, and how courts are currently interpreting those criteria in the context of device patents, is now an urgent operational priority.<\/p>\n\n\n\n

\n\n\n\n

Section VI: FDA Regulatory Exclusivities: The Non-Patent Protection Layer <\/h2>\n\n\n\n

Five-Year New Chemical Entity Exclusivity: The Baseline<\/strong><\/h3>\n\n\n\n

The 5-year new chemical entity (NCE) exclusivity is the foundational FDA-granted protection for drugs containing an active moiety never previously approved. It operates independently of patents: even if a drug had no Orange Book-listed patents at all, the 5-year NCE exclusivity would prevent the FDA from accepting an ANDA for 4 years from approval (if a Paragraph IV certification is anticipated) or 5 years in the absence of a patent challenge. NCE exclusivity begins from the NDA approval date, not the patent filing date, which means it provides a guaranteed protection window calibrated to the commercialization timeline rather than the R&D timeline.<\/p>\n\n\n\n

The NCE exclusivity is economically significant for drugs that reach approval with a narrow patent estate, either because they are developed from old scaffolds or because their primary patents were filed late in the development process. A drug with only 8 years of remaining patent life at NDA approval gets an effective 5-year exclusivity floor from NCE protection, reducing the LOE risk in the early commercial years when initial clinical adoption and market development investment is highest.<\/p>\n\n\n\n

Three-Year New Clinical Investigation Exclusivity: The Lifecycle Management Tool<\/strong><\/h3>\n\n\n\n

The 3-year new clinical investigation exclusivity applies to supplemental applications or new formulations that include new clinical studies essential to approval. This is the mechanism that gives lifecycle management strategies, such as extended-release formulations, new pediatric indications, and new dosage forms, a regulatory basis for exclusivity independent of patents.<\/p>\n\n\n\n

A product with a 3-year exclusivity for a new formulation prevents the FDA from approving an ANDA that relies on the new formulation’s approval for 3 years from that supplemental approval. Generic manufacturers seeking to market a bioequivalent version of the new formulation must wait out this period. The 3-year exclusivity does not, however, prevent generics from continuing to market the original formulation if it was already off-patent. This creates a strategic tradeoff: a new formulation protected by 3-year exclusivity may face competition from generic versions of the original formulation during the exclusivity period.<\/p>\n\n\n\n

Seven-Year Orphan Drug Exclusivity: High Value, Concentrated Risk<\/strong><\/h3>\n\n\n\n

The 7-year orphan drug exclusivity prevents the FDA from approving any other application for the same drug for the same orphan indication for 7 years from approval. It is the longest standard FDA exclusivity period and applies to drugs treating conditions affecting fewer than 200,000 people in the U.S.<\/p>\n\n\n\n

Orphan drug exclusivity has become a significant strategic tool. Drugs like lenalidomide (REVLIMID) received orphan exclusivity for multiple myeloma, which combined with patent protection to create an exceptionally long effective protection period. Pembrolizumab has received orphan designations for several tumor types, creating indication-specific exclusivity periods on top of its broader Orange Book patent portfolio.<\/p>\n\n\n\n

The strategic risk in orphan exclusivity is regulatory: if a competitor develops a drug that the FDA determines is ‘clinically superior’ to the orphan-designated product for the same indication, the FDA can approve the superior product even within the 7-year exclusivity period. The clinical superiority determination is made by the FDA based on safety, efficacy, or major contribution to patient care, and it is not an easy standard to meet, but it is not impossible. For products with orphan exclusivity as a primary market protection mechanism, the clinical differentiation story matters for IP valuation purposes.<\/p>\n\n\n\n

Pediatric Exclusivity: Six Months, Disproportionate Value<\/strong><\/h3>\n\n\n\n

Pediatric exclusivity adds 6 months to all existing patents and exclusivity periods for a drug when the sponsor conducts pediatric studies requested by the FDA under the Best Pharmaceuticals for Children Act. The studies do not need to result in a pediatric indication; they just need to be conducted and submitted. Six months of additional exclusivity on a drug generating $5 billion annually in U.S. revenue is worth approximately $2.5 billion in additional protected revenue, net of the cost of conducting the pediatric studies. For high-revenue products approaching their primary LOE date, pediatric exclusivity is consistently among the highest-return investments in the lifecycle management toolkit.<\/p>\n\n\n\n

Key Takeaways: Section VI<\/strong><\/h3>\n\n\n\n

FDA regulatory exclusivities operate in parallel with Orange Book patent protection and are often more durable: they cannot be challenged via IPR or Paragraph IV litigation the way patents can. For IP teams, the full exclusivity architecture for any product should map both the patent estate and all applicable regulatory exclusivity periods, with the binding constraint on LOE timing determined by whichever protection layer expires last. The interaction between multiple exclusivity types, NCE, orphan, 3-year new clinical, and pediatric, creates a compound exclusivity profile that can meaningfully extend effective market protection beyond what any single protection type would provide.<\/p>\n\n\n\n

\n\n\n\n

Section VII: The PTAB Battleground: IPR Institution Rates, Outcomes, and Settlement Dynamics <\/h2>\n\n\n\n

IPR Filing and Institution Rates in Biopharma<\/strong><\/h3>\n\n\n\n

The Patent Trial and Appeal Board (PTAB), established by the America Invents Act of 2011, provides a faster, more focused, and generally less expensive venue for patent validity challenges than federal district court. Inter partes review (IPR) proceedings are the primary mechanism, and biopharma-specific statistics reveal patterns that are directly relevant to portfolio management.<\/p>\n\n\n\n

Biopharma patents consistently account for 6-7% of total PTAB IPR filings, a small fraction relative to electrical and computer technology sectors, which account for approximately 69% of filings. This low filing volume is not a reflection of IPR’s irrelevance to the sector; it reflects the more concentrated patent portfolios in biopharma relative to consumer electronics or software, where individual products may implicate hundreds of patents. In biopharma, a single product typically has a more manageable portfolio, and litigants are more selective in which patents to challenge.<\/p>\n\n\n\n

The institution rate for biopharma IPR petitions runs higher than the overall average. In FY2024, biopharma petitions were instituted at a 73% rate versus a 68% cross-technology average. This means that three out of four biopharma IPR petitions challenging at least one claim demonstrate a ‘reasonable likelihood’ of prevailing, clearing the institution threshold. The higher institution rate reflects two factors: generic manufacturers tend to bring targeted, well-researched challenges rather than volume filings, and biopharma secondary patents, particularly formulation and method-of-use patents, often have narrower claims that are more susceptible to prior art arguments.<\/p>\n\n\n\n

Trial Outcomes: Why Institution Doesn’t Mean Cancellation<\/strong><\/h3>\n\n\n\n

Once a biopharma IPR is instituted, the claims’ survival rate in final written decisions has historically been higher than in other technology sectors. This apparent paradox, high institution but relatively strong survival in trial, reflects the layered nature of biopharma patent claims. Petitioners often challenge a patent with multiple grounds of invalidity; the PTAB may institute on some grounds but not others. When the trial proceeds, the innovator can focus its defense on the remaining instituted grounds, often demonstrating that the prior art combination relied on by the petitioner does not fully anticipate or render obvious the claimed subject matter.<\/p>\n\n\n\n

For composition-of-matter patents on biologics in particular, IPR challenges have a lower success rate than challenges to secondary small molecule patents. The complexity of biologic molecular characterization creates prior art uncertainty that tends to favor the innovator in a detailed factual inquiry. Formulation patents and method-of-use patents for small molecules, by contrast, face higher post-institution cancellation rates because prior art combinations for common formulation techniques are more accessible.<\/p>\n\n\n\n

The Settlement Dynamic: 32% of IPRs End Without a Final Decision<\/strong><\/h3>\n\n\n\n

In FY2024, 32% of all concluded PTAB IPR proceedings ended in settlement rather than a final written decision. This fraction is strategically significant. A settlement in the IPR context typically involves the challenger withdrawing its petition in exchange for some commercial concession from the patent holder, such as a licensing agreement, a supply agreement, or a negotiated market entry date. This mirrors the settlement dynamic in Paragraph IV district court litigation, where Hatch-Waxman ‘reverse payment’ settlements have been subject to antitrust scrutiny since the Supreme Court’s 2013 FTC v. Actavis decision.<\/p>\n\n\n\n

The Actavis decision held that ‘reverse payment’ settlements, where an innovator pays a generic manufacturer to abandon its patent challenge, are not categorically unlawful under antitrust law but are subject to rule-of-reason analysis. The practical consequence is that large cash payments from innovator to generic as consideration for entry date agreements are legally riskier than they were before 2013. Settlements structured around non-cash consideration, authorized generic agreements, supply agreements, or co-promotion arrangements, carry lower antitrust exposure but are still subject to case-by-case scrutiny.<\/p>\n\n\n\n

Investment Strategy: Reading PTAB Activity as a Signal<\/strong><\/h3>\n\n\n\n

For analysts and portfolio managers, IPR petition activity at the PTAB is an early-warning signal for LOE risk. A well-resourced generic manufacturer filing an IPR petition against a secondary patent in a drug’s Orange Book portfolio signals two things: the generic is preparing an ANDA and intends to challenge the patent estate, and the specific patent challenged may be vulnerable on the grounds cited in the petition. A high-quality IPR petition, one that identifies multiple strong prior art references, can shift market probability estimates for LOE timing by several years.<\/p>\n\n\n\n

PTAB docket monitoring should be a standard component of pharmaceutical IP intelligence for any analyst covering innovator companies with products approaching patent expiration. The PTAB’s public docket provides petition filing dates, institution decisions, and final written decisions on a near-real-time basis.<\/p>\n\n\n\n

Key Takeaways: Section VII<\/strong><\/h3>\n\n\n\n

PTAB IPR proceedings are more likely to be instituted for biopharma challenges than the cross-technology average suggests, but instituted proceedings survive in whole or part more often than in other sectors. The 32% settlement rate means that a third of all IPR challenges convert to commercial negotiations rather than legal verdicts. For innovators, early settlement of IPR proceedings targeting secondary patents may be preferable to the risk of claim cancellation that would weaken the Orange Book portfolio for subsequent ANDA challenges. For generic manufacturers, a successful IPR that cancels a key patent can eliminate a 30-month stay for an entire category of generic challengers.<\/p>\n\n\n\n

\n\n\n\n

Section VIII: Two Agencies, Two Mandates: USPTO Findings vs. FTC Enforcement <\/h2>\n\n\n\n

The Legal Mandate Divide<\/strong><\/h3>\n\n\n\n

The coexistence of the USPTO’s largely validating study and the FTC’s aggressive enforcement campaign is not contradictory. It reflects the distinct statutory mandates of the two agencies.<\/p>\n\n\n\n

The USPTO asks a patent law question under 35 U.S.C.: does the claimed invention satisfy the statutory requirements of novelty, utility, and non-obviousness? When the USPTO grants a patent, it affirms that the answer is yes by the preponderance-of-the-evidence standard applicable in examination. The USPTO’s study reflects this perspective: its analysis treats the existence of a validly granted patent as presumptive evidence of legitimate innovation, and its methodology measures only the market outcomes associated with Orange Book-listed, granted patents.<\/p>\n\n\n\n

The FTC asks a competition law question under Section 5 of the FTC Act: does the act of listing a particular patent in the Orange Book constitute an ‘unfair method of competition’ because its purpose and effect is to trigger an automatic 30-month stay that improperly delays generic competition? The FTC’s analysis does not turn on whether the patent is validly granted. A device patent on an asthma inhaler can be a perfectly valid patent under 35 U.S.C. and simultaneously be an improperly listed Orange Book patent under the FTC’s Section 5 analysis, if the patent does not legally ‘claim the drug’ under the Hatch-Waxman listing criteria.<\/p>\n\n\n\n

This legal distinction is the core of the regulatory tension. The two agencies are not disagreeing about whether secondary patents are legitimate. They are applying different legal frameworks to the same set of facts.<\/p>\n\n\n\n

The FTC’s Enforcement Campaign: Warning Letters, Delistings, and Amicus Activity<\/strong><\/h3>\n\n\n\n

The FTC’s September 2023 policy statement declared that improper Orange Book patent listings can violate Section 5 of the FTC Act. The statement was followed by concrete enforcement actions that provide the most direct test of the FTC’s legal theory to date.<\/p>\n\n\n\n

In two waves of enforcement, the FTC sent warning letters to multiple companies, challenging more than 400 Orange Book listings for products including semaglutide (OZEMPIC, VICTOZA), fluticasone\/salmeterol (ADVAIR), and budesonide\/formoterol (SYMBICORT) combinations, among others. The mechanism triggered by FTC notification requires the patent holder to either voluntarily delist the challenged patent or certify under penalty of perjury that the listing complies with statutory requirements. Several companies, including Boehringer Ingelheim and AstraZeneca for specific listings, voluntarily delisted patents following FTC notice, which is evidence that some listings were either genuinely improper or that the litigation risk of defending them outweighed the 30-month stay benefit.<\/p>\n\n\n\n

The FTC also filed amicus briefs in Teva v. Amneal and Mylan v. Sanofi, arguing in each case that improper Orange Book listings cause direct harm to competition and consumers by blocking lower-cost generic alternatives through improper triggering of the 30-month stay. These amicus filings signal that the FTC intends to develop case law supporting its Section 5 theory across multiple district court circuits, not just in enforcement proceedings at the agency level.<\/p>\n\n\n\n

Belcher Pharma and the Consistency Problem<\/strong><\/h3>\n\n\n\n

One specific focus of the USPTO-FDA collaboration, which the study mentions but does not develop fully, is the consistency of representations made by drug manufacturers to the two agencies. The Federal Circuit decision in Belcher Pharma v. Hospira involved exactly the scenario the agencies are trying to address: a manufacturer described a change to its drug product as a minor modification in submissions to the FDA (to secure a straightforward approval pathway), while simultaneously arguing to the USPTO that the same change was a non-obvious, patentable invention deserving a new patent.<\/p>\n\n\n\n

If this inconsistency is widespread, and there are reasons to believe it may be, it suggests a systematic problem in the interface between the two regulatory systems. FDA submissions describing innovations as minor are public documents available to USPTO examiners via patent office information resources. When examiners use those submissions as evidence in obviousness rejections, applicants who have characterized their innovation to the FDA as routine face a difficult patent prosecution challenge. The USPTO’s collaboration initiative to provide examiners with training on using FDA documentation in prior art searches directly targets this inconsistency.<\/p>\n\n\n\n

Key Takeaways: Section VIII<\/strong><\/h3>\n\n\n\n

The regulatory environment for pharmaceutical patent strategy in 2025-2026 requires simultaneous compliance with patent law standards and evolving FTC competition law standards. These are different frameworks with different thresholds, and compliance with one does not guarantee compliance with the other. For IP teams, every Orange Book listing decision should be reviewed against the FTC’s articulated standard for listing eligibility, not just the FDA’s ministerial listing rules. For commercial leads and CFOs, the FTC enforcement campaign introduces a new category of revenue risk: listings that generate 30-month stay protection may be subject to retroactive challenge and delisting, potentially accelerating LOE timelines.<\/p>\n\n\n\n

\n\n\n\n

Section IX: Terminal Disclaimers: The Legal Mechanism Enabling Thicket Construction <\/h2>\n\n\n\n

How Terminal Disclaimers Work<\/strong><\/h3>\n\n\n\n

A terminal disclaimer is a legal instrument filed in patent prosecution to overcome a ‘nonstatutory double patenting’ rejection. This rejection occurs when a patent examiner determines that a pending application claims an invention that is not identical to, but is an obvious variation of, an invention in an earlier, commonly owned patent. Double patenting rejections are designed to prevent patent applicants from improperly extending the term of a patent by filing a series of obvious variations.<\/p>\n\n\n\n

The terminal disclaimer resolves the rejection by having the applicant voluntarily agree that the new patent will expire on the same date as the earlier patent. Both patents remain in force until that shared expiration date, but neither extends the monopoly period beyond what the earlier patent would have provided. From the USPTO’s perspective, this is the mechanism functioning correctly: it prevents term extension while allowing the later patent to issue.<\/p>\n\n\n\n

The problem that critics identify, and that a proposed but withdrawn USPTO rulemaking acknowledged, is that terminal disclaimers enable the multiplication of legally distinct property rights around a single inventive concept. Each patent tied together by a terminal disclaimer is independently enforceable. A generic manufacturer challenging the entire terminally disclaimed family must defeat each patent in separate proceedings. For a family of 50 terminally disclaimed patents, as Humira reportedly has, that represents 50 separate litigation targets, each requiring independent litigation or IPR proceedings.<\/p>\n\n\n\n

The proposed USPTO rule, which would have rendered all patents in a terminally disclaimed family unenforceable if the founding patent was invalidated, would have fundamentally altered this calculus. An IPR petitioner who successfully invalidated the foundational patent would eliminate the entire family in a single proceeding. The rule was withdrawn without being finalized, but its consideration reflects the USPTO’s own internal acknowledgment that the terminal disclaimer system may be enabling thicket construction that its patent quality study downplays.<\/p>\n\n\n\n

Quantifying the Terminal Disclaimer Problem<\/strong><\/h3>\n\n\n\n

The Humira portfolio provides the most cited data point: one analysis identified 436 patents in the adalimumab portfolio linked by terminal disclaimers. For a generic manufacturer or biosimilar developer, challenging 436 legally distinct patents across multiple PTAB proceedings and potentially multiple district court litigations represents a cost that could run to hundreds of millions of dollars. That cost is itself a barrier to entry that does not require any individual patent to survive challenge. The barrier is the cumulative litigation burden, not the strength of any single patent.<\/p>\n\n\n\n

For IP valuation purposes, a portfolio with extensive terminal disclaimer linkage has a different risk profile than a portfolio with the same number of independent patents. A terminally disclaimed family all expiring on the same date creates a cliff rather than a gradual stepdown in patent protection. If the foundational patent is successfully challenged, the value of the entire terminally disclaimed family becomes uncertain. If the foundational patent survives, the entire family extends to its common expiration date.<\/p>\n\n\n\n

Legislative Proposals: ETHIC Act and Bipartisan Reform Efforts<\/strong><\/h3>\n\n\n\n

The Eliminating Thickets to Improve Competition (ETHIC) Act, introduced with bipartisan Senate support in July 2025 by Senators Welch, Braun, and Klobuchar, directly targets the terminal disclaimer problem. The bill would limit a patent holder to asserting a single patent from a terminally disclaimed family in litigation against any single challenger. If enacted, a biologic manufacturer with 436 terminally disclaimed patents could assert only one of them against any specific biosimilar developer. The deterrent value of the thicket would collapse, because a well-resourced biosimilar manufacturer would face only a single patent challenge per product, regardless of how large the terminally disclaimed family is.<\/p>\n\n\n\n

The ETHIC Act’s bipartisan sponsorship signals genuine legislative momentum, though the pharmaceutical industry’s lobbying resources are substantial and the bill’s path through committee is not guaranteed. For analysts modeling LOE risk for biologics with large terminally disclaimed portfolios, the ETHIC Act’s passage probability deserves at least a 15-20% weight in scenario analysis given current political dynamics.<\/p>\n\n\n\n

Key Takeaways: Section IX<\/strong><\/h3>\n\n\n\n

Terminal disclaimers are the specific legal mechanism that enables the accumulation of patent thickets without extending the nominal patent term. The USPTO study’s conclusion that patent count does not correlate with exclusivity duration is technically correct within its framework and does not contradict the separate argument that terminal disclaimer-linked portfolios create disproportionate litigation burdens. The ETHIC Act represents the most operationally significant legislative risk to the current terminal disclaimer-based thicket strategy. IP teams at innovator companies with large terminally disclaimed biologic portfolios should be modeling portfolio vulnerability under an ETHIC Act scenario as part of standard lifecycle management planning.<\/p>\n\n\n\n

\n\n\n\n

Section X: Biologics and the 12-Year Exclusivity Window: BPCIA, Biosimilar Interchangeability, and the Patent Dance <\/h2>\n\n\n\n

The BPCIA Framework: A Different Competitive Architecture<\/strong><\/h3>\n\n\n\n

The Biologics Price Competition and Innovation Act (BPCIA), enacted as part of the Affordable Care Act in 2010, created the regulatory pathway for biosimilar and interchangeable biologic approvals. The BPCIA differs fundamentally from Hatch-Waxman in three ways that directly affect IP strategy.<\/p>\n\n\n\n

First, the BPCIA provides a 12-year reference product exclusivity period from the date of first licensure of the reference biologic, during which the FDA cannot approve a biosimilar application that relies on the reference product’s safety and efficacy data. This 12-year period is substantially longer than the 5-year NCE exclusivity available for small molecules under Hatch-Waxman. It provides an exclusivity floor for all biologics regardless of patent strength, ensuring that early biosimilar entry cannot occur even for biologics with weak or nonexistent patent protection.<\/p>\n\n\n\n

Second, the BPCIA established the ‘patent dance,’ a structured information exchange process by which the reference product sponsor and the biosimilar applicant negotiate which patents will be litigated and when. The biosimilar applicant must provide its manufacturing process information to the reference product sponsor, who then identifies patents it believes the biosimilar would infringe. The parties negotiate a list of patents to litigate in the first wave of litigation, with remaining patents available for assertion in subsequent litigation waves. The patent dance is designed to provide structured, early resolution of patent disputes for complex biologics.<\/p>\n\n\n\n

Third, biosimilar interchangeability (a designation that allows pharmacists to substitute the biosimilar for the reference biologic without a new prescription) requires demonstrating that the biosimilar produces the same clinical result in any patient and, for products administered more than once, that switching between the reference product and the biosimilar does not result in greater risk than continuous use of either. Interchangeability is a higher standard than simple biosimilarity, and achieving it is clinically and analytically demanding.<\/p>\n\n\n\n

The IP Valuation Impact of the 12-Year Cliff<\/strong><\/h3>\n\n\n\n

The BPCIA’s 12-year exclusivity creates a specific IP valuation architecture for biologics. For a biologic approved in 2015, the 12-year exclusivity runs to 2027. Any patents on the biologic that expire before 2027 have no LOE impact, because the statutory exclusivity is the binding constraint. Patents expiring after 2027 become the operative barrier to biosimilar entry once the exclusivity period ends.<\/p>\n\n\n\n

This creates a valuation split: patents with expiration dates before the 12-year exclusivity cliff have zero marginal IP value (they are not the binding constraint), while patents expiring after the cliff have full marginal IP value (they are the operative barrier). IP teams should map the entire patent portfolio against the BPCIA exclusivity expiration to identify which patents actually contribute to protected revenue.<\/p>\n\n\n\n

For Keytruda, discussed in Section IV, the interplay between the 12-year BPCIA exclusivity (expiring around 2026 for the original approval) and the primary PD-1 antibody patents (expiring around 2028) means that the BPCIA exclusivity was the binding constraint through approximately 2026, after which the primary patents become the operative barrier. The 129+ secondary patents covering subcutaneous formulations and combination therapy methods have value only to the extent they create barriers to biosimilar interchangeability or to combination-specific biosimilar applications after 2028.<\/p>\n\n\n\n

Biosimilar Interchangeability as an IP Moat<\/strong><\/h3>\n\n\n\n

Reference product sponsors have recognized that the interchangeability designation creates a secondary competitive moat. If a biosimilar does not achieve interchangeability designation, pharmacists in most states cannot substitute it automatically at the point of dispensing. Patients must receive a new prescription specifically for the biosimilar. This administrative barrier reduces biosimilar uptake even after technical approval, because the automatic substitution that drives rapid generic market share for small molecules does not apply to non-interchangeable biosimilars.<\/p>\n\n\n\n

The reference product sponsor’s ability to design its reference product to make interchangeability more difficult to demonstrate, for example by relying on complex dosing algorithms or patient-specific titration, represents a form of competitive strategy that does not involve Orange Book listings or patent litigation but achieves similar market protection effects. For IP teams and commercial strategists at innovator companies, the interchangeability barrier is a legitimate element of lifecycle planning. For biosimilar developers, achieving interchangeability is a significant differentiator because it enables automatic substitution, driving higher market share more rapidly.<\/p>\n\n\n\n

Key Takeaways: Section X<\/strong><\/h3>\n\n\n\n

The BPCIA creates a fundamentally different competitive architecture than Hatch-Waxman. The 12-year exclusivity floor means that biologics have guaranteed protection regardless of patent strength, which changes the IP valuation model relative to small molecules. The patent dance structures biologic patent litigation in waves, which affects litigation strategy and settlement timing. Biosimilar interchangeability creates a commercially meaningful distinction between biosimilar designations that has no small molecule analog. For analysts covering biologics-heavy portfolios, the 12-year exclusivity cliff and the interchangeability competitive dynamic must be modeled explicitly.<\/p>\n\n\n\n

\n\n\n\n

Section XI: Technology Roadmap: Evergreening Tactics Across the Drug Lifecycle <\/h2>\n\n\n\n

Stage 1: Pre-NDA – Composition-of-Matter and Crystal Form Patents<\/strong><\/h3>\n\n\n\n

The foundation of any drug’s IP estate is laid before NDA filing. Composition-of-matter patents on the active pharmaceutical ingredient (API) are the broadest and most valuable patents in the portfolio. For small molecules, these patents typically cover the new chemical entity and its pharmaceutically acceptable salts. The filing date for these patents is generally early in clinical development, giving them a patent term that partially overlaps with the clinical development period. Patent term extension (PTE) under 35 U.S.C. 156 is available to restore a portion of the patent term lost during FDA review, with a maximum restoration of 5 years and a cap such that the total patent term remaining after extension does not exceed 14 years.<\/p>\n\n\n\n

Crystal form patents, covering polymorphic, amorphous, or other solid-state forms of the API, are a common secondary filing made during or after Phase II development. The polymorph most suitable for formulation development is typically identified during pre-formulation studies, and a patent covering that specific form can provide protection even after the composition-of-matter patent on the API itself expires, if the formulation developed for commercial use requires or preferentially uses the patented polymorph.<\/p>\n\n\n\n

Stage 2: Formulation and Manufacturing Process Patents<\/strong><\/h3>\n\n\n\n

Formulation patents covering specific excipients, drug-excipient ratios, particle size ranges, or controlled-release mechanisms represent the primary evergreening layer for most small molecule drugs. For an extended-release formulation requiring a specific polymeric matrix with defined release kinetics, the formulation patent covers the commercial product even if the API composition-of-matter patent has expired. A generic manufacturer seeking to market a bioequivalent extended-release formulation must either design around the formulation patent or challenge it via Paragraph IV.<\/p>\n\n\n\n

Manufacturing process patents are particularly relevant for biologics and complex small molecule APIs where the synthesis or purification process is non-obvious and difficult to replicate. For biologics, manufacturing process patents covering cell culture conditions, purification steps, or fill-finish parameters are often more durable than formulation patents because the technical complexity makes design-around paths limited.<\/p>\n\n\n\n

Stage 3: Method-of-Use Patents and New Indications<\/strong><\/h3>\n\n\n\n

Method-of-use patents are filed throughout the commercial lifecycle as new clinical data emerges. A drug approved for a single indication may accumulate method-of-use patents as clinical evidence demonstrates efficacy in additional diseases or patient populations. These patents do not prevent generic entry for the original indication: under the doctrine of carve-outs (‘skinny labeling’), generic manufacturers can omit the patented indication from their label and market a bioequivalent version for the non-patented uses.<\/p>\n\n\n\n

However, method-of-use patents can be strategically valuable in two ways. First, they prevent generic manufacturers from actively marketing and promoting the drug for the patented indication, which limits the commercial potential of the generic product if the patented indication represents a significant fraction of market use. Second, for biologics, method-of-use patents on combination regimens (such as pembrolizumab plus chemotherapy) can prevent biosimilar manufacturers from marketing their product with a label that matches the reference biologic’s combination indication, limiting biosimilar market access in high-value indication segments.<\/p>\n\n\n\n

Stage 4: Device and Delivery System Patents<\/strong><\/h3>\n\n\n\n

Device patents on delivery systems, inhalers, autoinjector pens, transdermal patches, and implantable devices, are the most contested layer of the current evergreening debate. These patents cover genuine innovations: device improvements that improve patient adherence, reduce administration errors, or extend the shelf life of the drug. The patent eligibility of these innovations is clear. The contested question is whether they belong in the Orange Book.<\/p>\n\n\n\n

For IP teams, the current landscape requires a clear-eyed assessment of each device patent’s listing eligibility under the FTC’s stated criteria. The FTC’s position is that a patent on a delivery device ‘claims the device, not the drug,’ and therefore is not eligible for Orange Book listing regardless of how essential the device is to drug delivery. If courts uphold this interpretation, device patents would remain valid and enforceable but would lose their 30-month stay trigger, significantly reducing their competitive value.<\/p>\n\n\n\n

Stage 5: Pediatric Exclusivity and REMS Strategies<\/strong><\/h3>\n\n\n\n

The final stage of the evergreening lifecycle involves extracting maximum value from the regulatory exclusivity and REMS architecture. As described in Section VI, pediatric exclusivity adds 6 months to all existing protections in exchange for conducting pediatric studies. REMS programs, while designed primarily for safety, can create operational barriers to generic development if managed in ways that restrict reference product access, as the Celgene\/lenalidomide case illustrates.<\/p>\n\n\n\n

For products with REMS programs, IP teams and regulatory affairs departments should work together to ensure that REMS-related patent listings and data exclusivity claims are clearly differentiated from safety program administration. The FTC has demonstrated willingness to pursue antitrust remedies when REMS is used in ways it characterizes as pretextual competitive barriers.<\/p>\n\n\n\n

Key Takeaways: Section XI<\/strong><\/h3>\n\n\n\n

The evergreening technology roadmap runs from pre-NDA crystal form patents through post-approval device and REMS strategies. Each layer has different strength, different legal risk, and different commercial value. The most defensible layers are composition-of-matter and manufacturing process patents. The most contested are device patents and REMS-adjacent strategies. For lifecycle management planning, the goal is to build the maximum number of genuinely inventive, legally defensible layers, not the maximum number of patents. Quantity without quality invites both IPR challenge and FTC scrutiny.<\/p>\n\n\n\n

\n\n\n\n

Section XII: Investment Strategy: Signals, Risks, and Portfolio Positioning <\/h2>\n\n\n\n

LOE Modeling: Building a Probability-Weighted Exclusivity Calendar<\/strong><\/h3>\n\n\n\n

Standard analyst LOE models treat patent expiration dates as the primary input. This is insufficient. A rigorous LOE model for any pharmaceutical asset should incorporate seven input variables: the projected expiration of each Orange Book-listed patent, the survival probability of each patent under IPR challenge, the number and quality of ANDA filers identified in FDA ANDA filing databases, the probability and likely terms of any patent litigation settlement, the applicable FDA regulatory exclusivity periods, any REMS-related barriers that could delay generic development, and the manufacturing complexity of the drug, particularly for complex dosage forms or biologics.<\/p>\n\n\n\n

For each of these inputs, scenario analysis should model at least three outcomes: base case (no successful patent challenge, LOE at primary patent expiration or exclusivity period end, whichever is later), upside case for generics (successful IPR or Paragraph IV challenge accelerating LOE by 2-4 years), and downside case for generics (failed challenges, prolonged litigation, LOE delayed to the last patent expiration in the Orange Book portfolio).<\/p>\n\n\n\n

Signal Reading: Monitoring the ANDA and Patent Litigation Dockets<\/strong><\/h3>\n\n\n\n

Three public data sources provide the most actionable early signals for LOE timing changes. First, the FDA’s Paragraph IV Certification List, published monthly, identifies drugs for which Paragraph IV challenges have been filed. A Paragraph IV filing is the first public signal that a generic manufacturer has committed to entering the market and believes it can challenge the patent estate. Second, PTAB’s public IPR docket identifies challenges to individual patents. An IPR petition targeting a key Orange Book patent, particularly one from a well-resourced generic manufacturer with a track record of successful PTAB challenges, is a strong signal that the patent’s survival probability should be discounted. Third, federal court PACER dockets provide the status of Hatch-Waxman litigation, including settlement agreements, which often specify a generic entry date that can be treated as a near-certain LOE date once executed.<\/p>\n\n\n\n

FTC Enforcement Risk: Assessing Orange Book Listing Vulnerability<\/strong><\/h3>\n\n\n\n

For innovator companies with products in the GLP-1, inhaled respiratory, or injectable biologic device categories, FTC enforcement risk is a specific LOE accelerant that most standard models do not incorporate. An FTC-forced delisting of a device patent eliminates the 30-month stay that patent was providing. If the delisted patent was the last or primary source of 30-month stay protection for the product, the effective LOE date could accelerate by 2.5 years from the date of delisting.<\/p>\n\n\n\n

For analysts covering Novo Nordisk, Eli Lilly, AstraZeneca, or GlaxoSmithKline positions with significant GLP-1 or inhaled therapy revenue, the probability and timing of FTC-driven delistings in those franchises is a material variable that belongs in LOE sensitivity analysis. The probability should be calibrated to the specifics of each challenged listing: device patents on purely mechanical components of an autoinjector are most vulnerable. Patents on the drug-device combination’s stability or compatibility are more defensible.<\/p>\n\n\n\n

Biosimilar Entry Timing: Portfolio Manager’s Checklist<\/strong><\/h3>\n\n\n\n

For products approaching biosimilar entry, the relevant checklist for portfolio managers includes eight factors: the BPCIA 12-year exclusivity expiration date, the primary biologic composition-of-matter patent expiration, the number of biosimilar BLA applications filed with the FDA and their approval status, the interchangeability designation status of each approved biosimilar, the patent dance litigation status between the reference product sponsor and each biosimilar applicant, any publicly disclosed settlement agreements specifying U.S. market entry dates, the pricing dynamics of biosimilar entry in analogous therapeutic classes (adalimumab biosimilars entered at 5-85% discounts to Humira’s list price depending on channel), and whether the ETHIC Act or similar legislation is in the bill-to-law pipeline.<\/p>\n\n\n\n

Short-Horizon Catalysts: FTC Actions and Legislative Developments<\/strong><\/h3>\n\n\n\n

The specific events that could materially move LOE dates for major pharmaceutical franchises in 2026-2027 include: final court decisions in the FTC-initiated device patent listing cases for GLP-1 drugs, the PTAB’s final written decisions in any pending IPRs targeting Keytruda or Dupixent secondary patents, potential ETHIC Act markup in the Senate Judiciary Committee, any Supreme Court grant of certiorari on an FTC Act Section 5 case arising from the Orange Book enforcement campaign, and the FDA’s regulatory action on any pending biosimilar interchangeability applications for high-revenue biologics.<\/p>\n\n\n\n

\n\n\n\n

Section XIII: Strategic Imperatives for IP Teams and R&D Leads <\/h2>\n\n\n\n

For Innovator IP Teams: Quality Over Quantity, and Compliance With Two Frameworks<\/strong><\/h3>\n\n\n\n

The era of building large patent portfolios as a quantity-based deterrence strategy is closing. The FTC’s enforcement campaign has introduced antitrust risk into the Orange Book listing process. The PTAB’s high institution rate for biopharma challenges means that weak secondary patents are increasingly likely to face IPR and lose. The ETHIC Act, if passed, would eliminate the principal litigation advantage of terminally disclaimed patent families.<\/p>\n\n\n\n

The correct response is not to stop filing secondary patents. It is to build secondary patents around genuinely inventive, clinically meaningful improvements and to subject every Orange Book listing decision to a dual-framework analysis: does this patent satisfy the Hatch-Waxman listing criteria (it claims the drug substance, a drug formulation, or a method of using the drug), and does listing this patent meet the FTC’s articulated standard for what constitutes an ‘unfair method of competition’ if its primary function is to trigger a 30-month stay rather than to reflect a legitimate IP claim on the drug itself?<\/p>\n\n\n\n

For R&D leads, this means that patent strategy should be integrated into development planning from the earliest stages. Formulation choices, delivery system design decisions, and indication expansion strategies all carry patent implications that should be assessed before development investment is committed. A formulation patent on a polymer matrix with genuine novelty over the prior art is a defensible IP asset. A formulation patent on a minor excipient concentration change that the prior art fully anticipates is an IPR target and an FTC risk, not a meaningful competitive asset.<\/p>\n\n\n\n

For Generic Manufacturers: Portfolio Analysis and Prioritization<\/strong><\/h3>\n\n\n\n

Generic manufacturers face a resource allocation challenge. The number of branded products with significant patent estates and commercially attractive revenue profiles far exceeds any single generic company’s capacity to challenge all of them simultaneously. Prioritization requires a systematic assessment of several factors for each potential target product: the revenue available during the 180-day first-filer exclusivity window, the estimated cost of Paragraph IV litigation through trial (often $5-15 million for a full trial), the survival probability of the key Orange Book patents under IPR challenge and Paragraph IV litigation, the number of other generic manufacturers likely to file first-filer applications for the same product, the manufacturing complexity and bioequivalence requirements, and any REMS or regulatory barriers that add development cost and timeline.<\/p>\n\n\n\n

The highest-return targets are products with large revenues, patent estates with identifiable vulnerabilities (strong IPR grounds, prior art that clearly anticipates the claimed formulation or method), limited competition from other generic filers, and straightforward bioequivalence requirements. Products with complex manufacturing requirements or extensive patient populations requiring risk management programs add cost and timeline that erode the first-filer economics.<\/p>\n\n\n\n

For Biosimilar Developers: The Interchangeability Strategic Decision<\/strong><\/h3>\n\n\n\n

The decision of whether to pursue an interchangeability designation for a biosimilar is a strategic question with significant commercial consequences. Interchangeability enables automatic pharmacist substitution, which drives rapid market share penetration. The clinical studies required to demonstrate interchangeability (typically one or more switching studies demonstrating no additional safety or efficacy risk from alternating between the reference product and the biosimilar) add cost and development time.<\/p>\n\n\n\n

For high-volume, high-revenue reference biologics where patient adherence and formulary access are critical, the commercial value of interchangeability likely exceeds the development cost in most cases. For specialty biologics with complex patient populations, limited patient volume, or reference products already losing market share to competing branded biologics, the interchangeability investment calculation may not be favorable.<\/p>\n\n\n\n

The reference product sponsor can influence the difficulty of demonstrating interchangeability through product design choices that affect switching study complexity. IP teams at innovator companies should work with clinical development colleagues to assess whether product features that complicate switching studies can be incorporated into lifecycle management planning without compromising patient outcomes.<\/p>\n\n\n\n

\n\n\n\n

Section XIV: Legislative Horizon: ETHIC Act, Terminal Disclaimer Reform, and What Comes Next <\/h2>\n\n\n\n

The ETHIC Act: Mechanics and Probability<\/strong><\/h3>\n\n\n\n

The Eliminating Thickets to Improve Competition Act, introduced in July 2025 by Senators Welch (D-VT), Braun (R-IN), and Klobuchar (D-MN), would amend the Patent Act to limit a patent holder to asserting only one patent from a terminally disclaimed family in any litigation against a single alleged infringer. This reform would not invalidate any patent. It would leave the entire terminally disclaimed family in force but restrict the ability to use that family as a multi-patent litigation burden.<\/p>\n\n\n\n

The practical consequence for biologics with large terminally disclaimed portfolios is significant. AbbVie’s 436-patent terminally disclaimed Humira portfolio, for example, would become a one-patent-at-a-time litigation portfolio under the ETHIC Act framework. A biosimilar manufacturer could, in theory, fight a single patent to conclusion without facing the prospect of sequential litigation across the remaining family. The deterrent value of the thicket would be fundamentally compromised.<\/p>\n\n\n\n

Legislative probability analysis for the ETHIC Act requires acknowledging the pharmaceutical industry’s strong lobbying presence in both parties. The bill’s bipartisan sponsorship is real, but pharmaceutical patent reform has repeatedly stalled in committee in previous legislative cycles. The current political environment, with drug pricing remaining a voter concern, provides stronger tailwind for reform than previous sessions. A scenario in which the ETHIC Act passes in modified form, perhaps with grandfather provisions for existing portfolios, is plausible within the 119th Congress.<\/p>\n\n\n\n

USPTO Terminal Disclaimer Rulemaking: The Withdrawn Proposal and Its Potential Revival<\/strong><\/h3>\n\n\n\n

The USPTO’s 2023 proposed rulemaking, which would have rendered all patents in a terminally disclaimed family unenforceable if a foundational patent in the family was invalidated, was more aggressive than the ETHIC Act’s litigation restriction approach. The proposed rule was withdrawn before finalization, citing concerns about legal authority and industry opposition. However, the underlying policy rationale has not been abandoned.<\/p>\n\n\n\n

A future USPTO rulemaking could revive the core concept in modified form, perhaps limiting the enforceability chain to patents where the terminal disclaimer was filed to overcome a double patenting rejection, rather than patents voluntarily disclaimed for strategic purposes. The administrative pathway for such a rulemaking would be cleaner if Congress first clarified the USPTO’s authority to regulate the enforceability of terminally disclaimed patents, which could be a companion provision to the ETHIC Act.<\/p>\n\n\n\n

Inter-Agency Coordination: The Path to a Coherent Policy<\/strong><\/h3>\n\n\n\n

The conflict between the USPTO’s generally validating findings and the FTC’s enforcement campaign reflects a structural gap in the U.S. regulatory framework for pharmaceutical IP. The agencies operate under different statutes, with different evidentiary standards and different definitions of harm. A coherent federal policy on pharmaceutical patent competition would require either statutory coordination mechanisms between the agencies or clear congressional guidance on the scope of Orange Book listing eligibility.<\/p>\n\n\n\n

One legislative approach under discussion in policy circles is granting the FDA a substantive (rather than purely ministerial) role in reviewing patent listing eligibility. Currently, the FDA accepts patent listings submitted by NDA holders without independently assessing whether the patents meet the statutory criteria. Giving the FDA authority to reject listings that fail the statutory test would shift the compliance burden to the point of listing rather than relying on post-hoc enforcement by the FTC or private litigation by generic manufacturers.<\/p>\n\n\n\n

Final Analysis: Where Risk Is Concentrated<\/strong><\/h3>\n\n\n\n

For pharma and biotech stakeholders entering the 2026-2028 period, the concentrated risk areas are identifiable. Biologics with large terminally disclaimed portfolios in therapeutic areas targeted by multiple well-funded biosimilar developers face the highest combined IPR, legislative, and FTC risk. GLP-1 franchise drugs with device patents currently listed in the Orange Book face the most immediate FTC enforcement exposure. Small molecule drugs with primary composition-of-matter patents expiring in the 2026-2030 window and weak secondary patent estates will see accelerated generic entry as PTAB institution rates remain elevated and generic manufacturers prioritize high-revenue targets.<\/p>\n\n\n\n

The USPTO’s study provides a useful empirical baseline: on average, the system delivers about 11.4 years of exclusivity for the drugs it measured, which is less than the 20-year statutory patent term and far less than the indefinite monopoly that the most aggressive critics describe. The study does not resolve the more granular questions about which specific products warrant policy concern, which patenting practices cross the line from lifecycle management to anticompetitive thicket construction, or how the FTC’s Section 5 theory will survive judicial review. Those questions are being answered now, in district court filings, PTAB proceedings, and congressional markup sessions. The stakeholders who read those signals accurately and adjust their IP strategy accordingly will have the most defensible positions as the landscape shifts.<\/p>\n","protected":false},"excerpt":{"rendered":"

Executive Summary and Key Findings The USPTO’s Drug Patent and Exclusivity Study, produced in collaboration with the FDA at the […]<\/p>\n","protected":false},"author":1,"featured_media":38197,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_lmt_disableupdate":"","_lmt_disable":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[10],"tags":[],"class_list":["post-23642","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-insights"],"modified_by":"DrugPatentWatch","_links":{"self":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/23642","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/comments?post=23642"}],"version-history":[{"count":2,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/23642\/revisions"}],"predecessor-version":[{"id":38198,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/23642\/revisions\/38198"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media\/38197"}],"wp:attachment":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media?parent=23642"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/categories?post=23642"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/tags?post=23642"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}